GENX — Genix Pharmaceuticals Share Price
Last trade - 00:00- CA$3.85m
- CA$4.99m
- CA$0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 355.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -476.2% | ||
| Operating Margin | -38417.36% | ||
Financial Summary
| Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.14 | n/a | n/a | n/a | 0.01 | n/a | n/a | -50.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms.
Directors
- Sina Salehi Pirooz CEO
- Danny Lee CFO
- Mahmoud Aziz DRC
- Kevin Bottomley IND
- Paul Chow IND (54)
- Jamie Lewin IND
- Darryl Yea IND
- Last Annual
- October 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- May 16th, 1998
- Public Since
- June 25th, 1996
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 59,224,131
- Address
- Suite 300, 1055 West Hastings St, VANCOUVER, V6E 2E9
- Web
- https://genixpharm.com/
- Phone
- +1 6046096198
- Auditors
- Buckley Dodds LLP
Similar to GENX
Avivagen
TSX Venture Exchange
BioNeutra Global
TSX Venture Exchange
Canyon Creek Food
TSX Venture Exchange
CubicFarm Systems
TSX Venture Exchange
Deveron
TSX Venture Exchange
FAQ
As of Today at 19:09 UTC, shares in Genix Pharmaceuticals are trading at CA$0.07. This share price information is delayed by 15 minutes.
Shares in Genix Pharmaceuticals last closed at CA$0.07 and the price had moved by +30% over the past 365 days. In terms of relative price strength the Genix Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +22.16% over the past year.
There is no consensus recommendation for this security.
Genix Pharmaceuticals does not currently pay a dividend.
Genix Pharmaceuticals does not currently pay a dividend.
Genix Pharmaceuticals does not currently pay a dividend.
To buy shares in Genix Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.07, shares in Genix Pharmaceuticals had a market capitalisation of CA$3.85m.
Here are the trading details for Genix Pharmaceuticals:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: GENX
Based on an overall assessment of its quality, value and momentum Genix Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genix Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +45.59%.
As of the last closing price of CA$0.07, shares in Genix Pharmaceuticals were trading -43.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genix Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genix Pharmaceuticals' management team is headed by:
- Sina Salehi Pirooz - CEO
- Danny Lee - CFO
- Mahmoud Aziz - DRC
- Kevin Bottomley - IND
- Paul Chow - IND
- Jamie Lewin - IND
- Darryl Yea - IND